Abstract
Objective This study aimed to compare infarct size and clinical outcomes in patients with proximal versus mid left anterior descending (mLAD) infarction. Background The extent of myocardium at risk is an important prognostic determinate in patients with ST-segment elevation myocardial infarction. Methods The INFUSE-AMI trial randomized patients with anterior ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention with bivalirudin anticoagulation to intracoronary (IC) bolus abciximab versus no abciximab and to thrombus aspiration versus no aspiration. The primary end point was magnetic resonance imaging infarct size (% of left ventricular mass) at 30 days. Lesion location was independently assessed and was defined as proximal (pLAD) if present before or at first significant septal perforator branch, or mLAD if beyond. Results Among 452 patients, 292 (64.7%) had pLAD and 159 (35.3%) had mLAD occlusions. Patients with pLAD infarcts were significantly more likely to have Killip class >1 heart failure and ejection fraction <40% and to present earlier to the hospital. Proximal LAD infarcts had significantly lower rates of final Thrombolysis In Myocardial Infarction flow 3 and procedural success but similar rates of myocardial blush grade 2/3 and ST-segment resolution compared with mLAD infarcts. Infarct size at 30 days was significantly greater in the pLAD group (19.3% [9.2-25.9] vs 14.3% [6.2-18.9], P <.0001). Mortality at 30 days was also higher in the pLAD group (4.2% vs 0.6%, P =.04). The effect of IC abciximab on reducing infarct size was comparable in both groups. Conclusion ST-segment elevation myocardial infarction caused by pLAD compared with mLAD occlusion results in larger infarcts and greater mortality even with contemporary reperfusion therapy.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 64-70 |
| Number of pages | 7 |
| Journal | American Heart Journal |
| Volume | 166 |
| Issue number | 1 |
| DOIs | |
| State | Published - Jul 1 2013 |
| Externally published | Yes |
Fingerprint
All Science Journal Classification (ASJC) codes
- Cardiology and Cardiovascular Medicine
Cite this
}
Infarct size and mortality in patients with proximal versus mid left anterior descending artery occlusion : The intracoronary abciximab and aspiration thrombectomy in patients with large anterior myocardial infarction (INFUSE-AMI) trial. / Brener, Sorin J.; Witzenbichler, Bernhard; Maehara, Akiko; Dizon, Joe; Fahy, Martin; El-Omar, Magdi; Dambrink, Jan Henk; Genereux, Philippe; Mehran, Roxana; Oldroyd, Keith; Parise, Helen; Gibson, C. Michael; Stone, Gregg W.
In: American Heart Journal, Vol. 166, No. 1, 01.07.2013, p. 64-70.Research output: Contribution to journal › Article
TY - JOUR
T1 - Infarct size and mortality in patients with proximal versus mid left anterior descending artery occlusion
T2 - The intracoronary abciximab and aspiration thrombectomy in patients with large anterior myocardial infarction (INFUSE-AMI) trial
AU - Brener, Sorin J.
AU - Witzenbichler, Bernhard
AU - Maehara, Akiko
AU - Dizon, Joe
AU - Fahy, Martin
AU - El-Omar, Magdi
AU - Dambrink, Jan Henk
AU - Genereux, Philippe
AU - Mehran, Roxana
AU - Oldroyd, Keith
AU - Parise, Helen
AU - Gibson, C. Michael
AU - Stone, Gregg W.
PY - 2013/7/1
Y1 - 2013/7/1
N2 - Objective This study aimed to compare infarct size and clinical outcomes in patients with proximal versus mid left anterior descending (mLAD) infarction. Background The extent of myocardium at risk is an important prognostic determinate in patients with ST-segment elevation myocardial infarction. Methods The INFUSE-AMI trial randomized patients with anterior ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention with bivalirudin anticoagulation to intracoronary (IC) bolus abciximab versus no abciximab and to thrombus aspiration versus no aspiration. The primary end point was magnetic resonance imaging infarct size (% of left ventricular mass) at 30 days. Lesion location was independently assessed and was defined as proximal (pLAD) if present before or at first significant septal perforator branch, or mLAD if beyond. Results Among 452 patients, 292 (64.7%) had pLAD and 159 (35.3%) had mLAD occlusions. Patients with pLAD infarcts were significantly more likely to have Killip class >1 heart failure and ejection fraction <40% and to present earlier to the hospital. Proximal LAD infarcts had significantly lower rates of final Thrombolysis In Myocardial Infarction flow 3 and procedural success but similar rates of myocardial blush grade 2/3 and ST-segment resolution compared with mLAD infarcts. Infarct size at 30 days was significantly greater in the pLAD group (19.3% [9.2-25.9] vs 14.3% [6.2-18.9], P <.0001). Mortality at 30 days was also higher in the pLAD group (4.2% vs 0.6%, P =.04). The effect of IC abciximab on reducing infarct size was comparable in both groups. Conclusion ST-segment elevation myocardial infarction caused by pLAD compared with mLAD occlusion results in larger infarcts and greater mortality even with contemporary reperfusion therapy.
AB - Objective This study aimed to compare infarct size and clinical outcomes in patients with proximal versus mid left anterior descending (mLAD) infarction. Background The extent of myocardium at risk is an important prognostic determinate in patients with ST-segment elevation myocardial infarction. Methods The INFUSE-AMI trial randomized patients with anterior ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention with bivalirudin anticoagulation to intracoronary (IC) bolus abciximab versus no abciximab and to thrombus aspiration versus no aspiration. The primary end point was magnetic resonance imaging infarct size (% of left ventricular mass) at 30 days. Lesion location was independently assessed and was defined as proximal (pLAD) if present before or at first significant septal perforator branch, or mLAD if beyond. Results Among 452 patients, 292 (64.7%) had pLAD and 159 (35.3%) had mLAD occlusions. Patients with pLAD infarcts were significantly more likely to have Killip class >1 heart failure and ejection fraction <40% and to present earlier to the hospital. Proximal LAD infarcts had significantly lower rates of final Thrombolysis In Myocardial Infarction flow 3 and procedural success but similar rates of myocardial blush grade 2/3 and ST-segment resolution compared with mLAD infarcts. Infarct size at 30 days was significantly greater in the pLAD group (19.3% [9.2-25.9] vs 14.3% [6.2-18.9], P <.0001). Mortality at 30 days was also higher in the pLAD group (4.2% vs 0.6%, P =.04). The effect of IC abciximab on reducing infarct size was comparable in both groups. Conclusion ST-segment elevation myocardial infarction caused by pLAD compared with mLAD occlusion results in larger infarcts and greater mortality even with contemporary reperfusion therapy.
UR - http://www.scopus.com/inward/record.url?scp=84879781866&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84879781866&partnerID=8YFLogxK
U2 - 10.1016/j.ahj.2013.03.029
DO - 10.1016/j.ahj.2013.03.029
M3 - Article
C2 - 23816023
AN - SCOPUS:84879781866
VL - 166
SP - 64
EP - 70
JO - American Heart Journal
JF - American Heart Journal
SN - 0002-8703
IS - 1
ER -